Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) now Eligible for Coverage through Veterans Affairs Canada and Indigenous Services Canada

TORONTO, Sept. 21, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA^® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed by Veterans Affairs Canada (VAC) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB) Program.

"We would like to thank Veterans Affairs Canada and Indigenous Services Canada for providing eligible ALS patients access to this treatment," said Atsushi Fujimoto, President, MTP-CA. "Including RADICAVA on these formularies is an important step to support those living with ALS who are eligible under the federal programs."

In addition to VAC and NIHB, RADICAVA is also listed on the:

• Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization)
• Ontario Drug Benefit Formulary (Exceptional Access Program)
• Alberta Drug Benefit List (special authorization)
• New Brunswick Drug Plan (NBDP) formulary (special authorization)
• Manitoba Drug Benefits and Interchangeability Formulary (special authorization)
• Saskatchewan Formulary (special authorization)
• Nova Scotia Drug Formulary (special authorization)
• British Columbia (BC) PharmaCare Formulary (special authorization)

MTP-CA continues to have discussions with other provinces regarding the listing of RADICAVA under additional publicly funded drug programs.

About RADICAVA^® (edaravone)
RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRSR).¹ Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.

About Mitsubishi Tanabe Pharma Canada, Inc.
Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit www.mt-pharma-ca.com.

About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.

__________________________________

¹ RADICAVA^® (edaravone) Canada Product Monograph. October 2019https://www.mt-pharma-ca.com/our-product/

SOURCE Mitsubishi Tanabe Pharma Canada, Inc.

Media inquiries: Debbie Etchison, 908-340-8578, [email protected]